Abstract
Purpose In nonischemic cardiomyopathy (NICM), CD34+ cell transplantation was shown to improve left ventricular dimensions and function. We sought to investigate the effects of such therapy on functional mitral regurgitation (FMR) in this patient cohort. Methods Of 134 consecutive patients with NICM (LVEF Results During follow-up, 2 patients died, and 1 underwent heart transplantation. In the remaining cohort we found improvement of FMR in 41/109 patients (38%, Group A), and in 68/109 (62%) FMR did not improve (Group B). At baseline, Groups A and B did not differ in age (53±11 years in Group A vs. 54±10 years in Group B, P=0.38), sex (male: 88% vs. 84%, P=0.57), creatinine (0.94±0.21 mg/dL vs. 1.00±0.30 mg/dL, P=0.27), bilirubin (0.92±0.45 mg/dL vs. 0.93±0.53 mg/dL, P=0.68), LVEF (31.7±7.7% vs. 30.6±8.0%, P=0.23), or NTproBNP levels (1620±1978 pg/mL vs. 1490±1984 pg/mL, P=0.73). In contrast, baseline end-diastolic volume (EDV) was significantly higher in Group A than in Group B (245±56 mL vs. 190±82 mL, P Conclusion Transendocardial CD34+ cell transplantation appears to be associated with an improvement in FMR in nonischemic cardiomyopathy patients with high EDV. Further studies are warranted to investigate whether such approach can be used in broader population of chronic heart failure patients or in conjunction with percutaneous mitral valve repair.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call